Friday, March 21, 2014

Synthetic Cannabinoids in Louisiana / Illnesses and Emergency Scheduling

It has been reported that over the last few weeks, hundreds of people have been treated after consuming synthetic cannabinoid containing products. Some of these patients have presented to the emergency department with "life threatening" symptoms. At this time, it is not known what exact symptoms or effects have been reported. It is also not known if any of these cases have been analytically confirmed via detection of drug or drug metabolite in a patient's blood, serum, plasma, or urine.

Today, Louisiana has emergency scheduled eight (8) synthetic cannabinoid compounds. The following compounds will now be considered Schedule I controlled substances in Louisiana. 

ADB-FUBINACA
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1-H-indazole-3-carboxamide

ADBICA
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1-H-indole-3-carboxamide

AB-FUBINACA
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide

5F-AB-PINACA 
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide

AB-PINACA
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-
carboxamide

FUBIMINA or AM-2201 benzimidazole derivative
(1-(5-fluoropentyl)-1H-benzimidazol-2-yl)(naphthalen-1-yl) methanone

Mepirapim
(4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl) methanone

FDU-PB-22
Naphthalen-1-yl-1-(4-fluorobenzyl)-1H-indole-3-carboxylate

LA House Bill 229 which is pending in Louisiana legislature already contained these compounds, as well as the designer opioid drug, Acetylfentanyl. 

AB-FUBINACA and ADB-PINACA were recently placed into Schedule I by the US Federal government. ADBICA and ADB-PINACA were also two compounds associated with the cluster of illnesses in Colorado in 2013. In late 2013, here at Dose Makes the Poison, the unknown nature of these "alphabet soup" compounds was also questioned.

If I see any updates on this story, I'll add to this post.

As always, stay safe.

Cheers,

FTG

No comments:

Post a Comment